Ascendis Pharma plans phase III study for next year
In about one year, Denmark’s Ascendis Pharma will begin phase III testing of its main asset. The company’s R&D costs increased in the most recent quarter.
BY BENJAMIN WERNER CHRISTENSEN
Danish-based biotech company Ascendis Pharma, which pulled of an IPO in the US earlier this year, is set to bring out the big guns. The company says in its semi-annual interim statement that it aims to send its main asset, growth hormone TransCon PEG hGH, into phase III testing in mid-2016.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Ascendis bags USD 111.5 million in IPO
For abonnenter
Sanofi ditches Danish insulin deal
For abonnenter
Ascendis sets IPO target
For abonnenter
